ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, and Menlo Park, CA. Its core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. The company'ss therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition that affects patients with chronic kidney disease, hypertension, diabetes, and/or chronic heart failure. Hyperkalemia is characterized by abnormally high concentrations of potassium in the blood. ZS-9 is currently being tested in late-stage clinical trials.

Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA.

Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. The Company's molecules, whose systemic exposure is severely restricted, target transporters and receptors, modulating the uptake of nutrients or inducing secretion of key hormones to produce a therapeutic benefit in patients. The Company's non-systemic products act from within the intestines to avoid potential side effects that could occur with systemic exposure. The Company's lead product, RDX5791, a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and for prevention of excess dietary sodium absorption, a new treatment modality for high blood pressure. RDX5791 is in phase 2 for IBS-C and a dose-ranging/regimen study for inhibition of excess dietary sodium absorption. Ardelyx is also developing RDX002, a minimally-absorbed, orally administered NaP2b phosphate transport inhibitor for the inhibition of phosphate absorption in patients with chronic kidney disease, and RDX009, a minimally-absorbed, orally administered TGR5 agonist for the treatment of type 2 diabetes through direct induction of intestinal incretins such as GLP-1 and PYY. Both RDX002 and RDX009 are in preclinical development. To date, Ardelyx has raised $56M in venture and angel funding since it was founded in 2007. Ardelyx is located in Fremont, California.

G.D. Searle, LLC is a wholly owned trademark of Pfizer. It is currently used mainly as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle). Prior to its 1985 merger with Monsanto, Searle was a company focusing on life sciences, specifically pharmaceuticals, agriculture, and animal health.

Otsuka Pharmaceutical Factory, Inc. manufactures and distributes pharmaceutical and nutritional products. Its products include medical foods, hine E-gel, processlead, engelead, innerpower, oronine h ointment, urepearl plus lotion 10 and urepearl plus cream. The company was founded on September 1, 1921 and is headquartered in Naruto, Japan.

Part of CSL Ltd., Vifor (International) AG is a Swiss company located in St. Gallen. The firm develops, manufactures and supplies pharmaceutical products.

It discovers and develops renal care pharmaceutical products. It develops non-absorbed polymeric phosphate and potassium binder compounds to treat chronic kidney diseases. The company, formerly known as Symyx Therapeutics, Inc. was founded in 2002 and is based in Santa Clara, California.

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive. The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

Adbiotech is a company that leaps toward the future with continuous challenges. Adbiotech is a research institute affiliated with the Korea Industrial Technology Association to research and develop antibody products, cosmetics and food additives for oral administration of pharmaceuticals, livestock and fisheries using egg yolk antibody (IgY) technology. Was established. They are leading national research projects for new and diverse products with the aim of "our food safe" through industry-academic cooperation.

Sanwa Kagaku Kenkyusho Co., Ltd. engages in the research, development, manufacture, and marketing of pharmaceuticals, diagnostics, medical and nursing care nutritionals, and healthcare products. The company also provides contract manufacturing services for pharmaceuticals. It offers products through a network of medical representatives worldwide. The company was founded in 1953 and is based in Nagoya, Japan. Sanwa Kagaku Kenkyusho Co., Ltd. operates as a subsidiary of Suzuken Co., Ltd.

Manufactures and sells pharmaceutical products

Solara Active Pharma Sciences Ltd. engages in the manufacture and development of active pharmaceutical ingredient. Its products include NSAID, anaesthetic, analgesics, antiviral, retinod, anti-emetic, antimalrial, diuretic, muscle relaxant, antiallergics, antihypertensive, calcimimetic agent, anti sezure, antigout, cardiovascular, anti-infective, cough suppressant, anti-ulcerative, anesthetic, antiepileptic, antirheumatic, skin disorder, cardiovascular agent, aplha or beta antagonist, hyperphosphatamia, atypical antipsychotic, antineoplastic adjunct, anti psoriasis, barbiturate dervicative, treatment of overactive bladder, gastro-intestinal, atypical antipsychotic, antihyperlipidemic, antihelmintic, gastrointestinal, antibiotic, phenylalanine reducer, anticholetithic, and anti depressant. The company was founded on February 23, 2017 and is headquartered in Chennai, India.

Jilin Maifu Nutrition Technology Co., Ltd., established on 2016-05-17, Business scope includes formula food for special medical purpose,Pre-packaged food,Healthy food,drinks,Production and sales of other formula foods for infants and young children;medical instruments(Ι,Class II),Manufacturing and sales of healthcare equipment;retail computer,Software and Auxiliary Equipment;Medical Research and Experimental Development;goods,Technology Import and Export;technology development,transfer,to promote,consultation service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Maifu Nutrition Technology (Beijing) Co., Ltd., established on 2012-02-10, Business scope includes technology transfer,Technology Promotion(Does not include agricultural technology extension),technology development,technical consulting,Technical Services;Import and export,Technology Import and Export,Agent import and export;Sales of medical devices(I,IIkind);Conference Services;Undertake exhibition and display activities;sell food.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Sale of food and items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Parion Sciences is a development stage company dedicated to research, development, and commercialization of treatments to restore patient’s innate mucosal surface defenses. In the eye and in the lung, our layer of protective mucus plays an important role in keeping our bodies healthy. Sometimes though, either through genetics, aging or environmental stimulus, our innate mucosal defense system can become compromised. Parion’s science driven technologies target respiratory and ocular diseases in which the patient’s ability to protect their mucosal surfaces is compromised

Waterstone Pharmaceuticals is a private US based company with research, development & manufacturing capabilities in Wuhan, China. Waterstone Pharmaceuticals engages in activities ranging from drug discovery of proprietary new chemical entities, custom development & manufacturing services, and generic drug development and manufacturing.